College Stock: Penny Stock News

It doesn’t take a rocket scientist to understand that IVOB’s INVOcell and FHCO’s Female Condom are intended for two different things; one to promote pregnancy, one to prevent it.  The companies seem vastly different, diametrically opposed even.  But the Dean implores his students to look closer… and discover the lucrative similarities.

IVOB and FHCO…
- Both started on the OTC Bulletin Board (with FHCO graduating to the AMEX and then recently the NASDAQ!)
- Both market innovative medical devices for women’s health that are inserted intra-vaginally
- Both received CE MARK approval for the EU and many other world markets first (with FHCO later receiving FDA approval!)
- Both have the same savvy Investor Relations company

In 2008, FHCO did $25 million in sales with a net income of nearly $5 million!

In order for IVOB to generate the same $25 million in sales, they would only need to attain approximately 57,000 patients out of the 150,000,000 infertile couples worldwide. That’s less than 1/30th of 1% (.00033333%) of the market.

With $25 million in sales, IVOB would have a $300 million market cap and $5-$6 price per share! … And that’s if they only reach 38 out of every 100,000 infertile women!

The numbers are staggering, to say the least, downright amazing if you consider those 50,000 patients amount to only 1% of the infertile couples in Pakistan.  1% of 1 country!  IVOB is now selling in countries on 5 continents!

Forget “rocket scientist” – You don’t even need to pass 8th grade math to see the possibilities here!  I want all my students to take a look at FHCO, take a look at IVOB … see if you don’t come to the same conclusions I have.

INVO Bioscience (IVOB) is on the cusp of becoming one of the biggest players in one of the fastest growing markets around – assisted reproductive technology.

Infertility rates are rising. It is currently estimated there are over 150 million infertile couples worldwide, yet less than 1/2 of 1% (that’s .003%) get treated with the current technology, in vitro fertilization. Why? Because it costs too much! But IVOB has developed technology less expensive that is just as effective!

And here’s the kicker – their device is PATENTED WORLDWIDE! Better yet, it has CE MARK approval, which is the equivalent to an FDA approval for the rest of the world!

This is no trial stage company. IVOB has already started selling the INVOcell device across the globe. The potential for profits is so huge, I believe this is a golden ground floor opportunity for The Dean’s students.

Just look at these numbers. The average cost of in vitro fertilization is $12,400. The INVOcell is sold for only $125-400 per unit making the procedure about ½ the cost of traditional treatment! Which do you think millions of infertile couples around the world will soon be buying?

INVOcell is the most significant development to hit the reproductive arena in over a decade! IVOB just attended the 25th annual ESHRE conference, the biggest infertility conference in the world, where it was the talk of the show! People are excited! And as my students know, when interest is rising, the price per share typically follows.

I encourage all my students to do further research and check out the excitement at IVOB’s website. The company has NO DEBT and believes their patents alone are worth more than their current market cap of $6 million. Plus, roughly two-thirds of the shares outstanding are owned by insiders, meaning the men and women behind IVOB are putting their own bottom lines… on the line!

For 150 million infertile couples worldwide, fertility has a new name… and it’s IVOB!

The Dean has discovered more reasons why IVOB is on the brink of something big!  Patented worldwide and with CE MARK approval, the INVOcell has officially… gone global!

Not only is IVOB’s device priced at a fraction of the cost compared to alternative technologies, the company is franchising INVO clinics throughout the world!

FRANCHISING – The concept that made “McNuggets” a household name.

In South and Central America, 17 INVO Centers are now open, thanks in part to Dr. Elkin Lucena, a man renowned for training doctors on in vitro fertilization (IVF) but who now trains them on INVOcell!

In Pakistan, 8 new INVO clinics just opened in April. With over 160 million people and the highest infertility rate in the world (21.9%), it stands to be a very lucrative position!

In India, a population of 1.2 billion people, IVOB works with physicians like Dr. Hrishikesh Pai, Chairman of the World Congress on infertility throughout India.  Dr. Pai owns 5 of the 30 IVF centers in the country, yet he’s positioning himself to be the profiteer throughout all of India on INVOcell!

In Europe, IVOB partnered with Dr. Peter Kemeter and Dr. Wilfried Feichstinger, two pioneers for IVF 20 years ago, who are now talking all about INVOcell!  Aside from building a training center for fertility specialists throughout the continent, Kemeter recently indicated that he plans for INVOcell to replace IUI (artificial insemination) in all of Austria, which would equate to $18 million potential revenue for IVOB!

In Canada, INVOcell just started making an impact in January, where the device is going for $400 per unit with a cost to manufacture UNDER $15!  Can you imagine the revenue that kind of profit margin is going to produce?!

And IVOB’s just getting started!  The company has now expanded to Switzerland, Spain, Italy… the list goes on!

What I want my students to realize is exactly what physicians worldwide already have – the potential for IVOB is too incredible to ignore.  Only 1% of the world market (150 million infertile couples) equates to $660 million in potential revenue!  ONE PERCENT! With the buzz surrounding this company growing at an exponential rate, it is staggering to imagine the possibilities.

Want real life examples of how The Dean’s SuperChirps are the best value on the internet for an embarrassingly low fee of $9.87 / month?

On July 15th The Dean sent a “SuperChirp” to 109 Honors Students. The message read:

“TheDean: I’m on the phone with $IVOB shareholders talking about an advertising campaign coming up soon.”

At the time of the initial SuperChirp, IVOB was trading at $0.10 and today the traded to $0.38 for a gain of 280% within 3 weeks.

What are you waiting for? Go now to Honors Student Signup on Superchirp.com

Want real life examples of how SuperChirps are the best value on the internet for an embarrassingly low fee of $9.87 / month?

On July 15th The Dean sent a “SuperChirp” to 109 Honors Students. The message read:

“TheDean: I’m on the phone with $IVOB shareholders talking about an advertising campaign coming up soon.”

At the time of the initial SuperChirp, IVOB was trading at $0.10 and today the stock closed at $0.31 for a gain of 210% within 3 weeks.

Now its August 6th and The Dean still hasn’t taught the entire student body about IVOB!

And its not just 6 blockbuster blogs to be disseminated throughout all corners of the internet starting this weekend. The Dean is also planning:

- A 2 minute Micro Cap Movie that will be so amazing that The Dean’s competitors will begin copycats right away.
- An upcoming television segment on the Wide World of Stocks featuring IVOB in a segment that will never be forgotten.
- One Stock Wiki that will have people questioning why IVOB isn’t a $100 million company already.

All of this is coming very soon and Honors Students have known about it for 3 weeks already! What are you waiting for? It’s the Ivy League of Investing for an embarrassingly low $9.87/month!

Honors Student Signup on Superchirp.com

Yesterday, $IVOB jumped from an opening of $0.16 to $0.295—a gain of 84%!

With a strong day yesterday, $IVOB opened today at $0.26 and moved up 26.9% to $0.33!

The Dean alerted his Honor Students to $IVOB and their INVOcell infertility device when the stock was at $0.10. If you signed up to be an Honor Student, you could have seen PROFITS of 230%!

INVO Bioscience ($IVOB) is a medical device company with an innovative infertility treatment that is patented worldwide. $IVOB‘s product is perhaps the most significant development in the reproductive arena in the past decade!

The Dean will be telling the entire CollegeStock Community more about $IVOB this weekend. $IVOB is another PROFITABLE example of why you should sign up to become an Honor Student!

The Dean and Wide World of Stocks is back for their second episode of information-packed Wide World of Stocks TV! This exhilarating episode will not only be available for viewing in 95 million homes but will also discuss why The Dean thinks $LBAS looks like a very interesting pick.

LBAS is up over 40% in the last week, and CollegeStock Honors Students who sign up for Superchirps had the opportunity to get in at the ground floor before anyone else in the community!  Don’t want to miss the next pick?  Sign up now!

Location Based Technologies, Inc. (LBAS) is an innovative technologies company setting out to apply and integrate its products and services to a potentially profitable mass market. $LBAS is quickly becoming known for their several easy to use and accurate PocketFinder devices that are lightweight and tougher than nails. Sound familiar? $LBAS PocketFinder software is already available for use on the iPhone, which currently has over 8.3 million active subscribers.

Knowing that the smartphone market is exploding, $LBAS has also worked a deal with the Google (GOOG) Android phone available through T-Mobile!

To ensure reliability of their super-lightweight products, $LBAS uses the same multibillion dollar satellite infrastructure used by the United States Department of Defense. Increasing their chances to explode in revenue, $LBAS plans to market its four products–PocketFinder, PocketFinder Plus, PetFinder and PocketFinder Luggage–to provide security and peace of mind to a wide range of consumers, including parents, pet owners and stores, elderly caretakers, and the trucking and logging industries.

$LBAS uses the latest in GPS and wireless technologies to fulfill their mission of “Linking People through Technology.” $LBAS is well on their way, already cashing in on two 7-figure deals!

The United States is said to have over 70 million pets and $LBAS has shown signs of marketability by landing a $3.7 million order for their PetFinder product! The Dean sees $LBAS as an interesting pick because there are several markets and applications for their tracking and location technologies.

Not an animal lover? $LBAS has also entered into the $645 billion trucking industry with a $3 million contract with LoadRack.com! Since this industry accounts for 83.8% of the nation’s freight, $LBAS hopes to keep on truckin’ and acquire similar and larger contracts.

$LBAS has a range of uses and can track children, special needs individuals, pets, cargo, personal luggage, and even the elderly. The United States spends over $1 trillion annually on providing Medicare and other services to the elderly population, leaving room for $LBAS to GROW. And that figure doesn’t even account for the money spent at some 16,000 privately owned nursing homes nationwide!

$LBAS can also look to profit from over 130,000 childcare businesses in the United States. And just think about the government funds that go into the hundreds of thousands of public schools that have students with special needs!

Tele Atlas (TAAGM.AS) polled United States phone users and 84% expressed interest in child-locator devices. The survey also revealed that 47% of mobile phone users were interested in friend-locator services. Today, everyone wants to keep in touch with their family and friends and this is done through the Internet and mobile phones. $LBAS could really CASH IN!

The Dean thinks that $LBAS can take advantage of this social networking phenomenon and, with so many applications for their products and services, you won’t have to look further than your own POCKET to FIND profits!

For more information visit:

LocationBasedTech.com

$IVOB has taken off!!! Opening this morning at $0.16, $IVOB has moved up 84% to $0.295 today!

Back on July 15, 2009, The Dean told his Honor Students about $IVOB at $0.10. This premier infertility treatment company has hit a high for a 195% gain!

The Dean will be featuring $IVOB this weekend to the rest of the CollegeStock Community.  Gains like these are the real value of being an Honors Student.

$IVOB’s exciting new product, the INVOcell, is a one-of-a-kind patented product. This revolutionary fertility product is not a drug but a treatment that makes possible the vaginal incubation of eggs, sperm and early stage embryo development. $IVOB has put all its efforts into this one life-changing product! The Dean is confident that many people around the wrld will be positively affected by this new INVOcell technology.

$IVOB has been marketing their product to in vitro fertilization (IVF) centers and physicians, directly and through distributors in Europe, Canada, Latin America and countries in the Middle East. In addition, The Dean has learned that $IVOB has initiated contracts for the purchase of the INVOcell devices in countries such as Turkey, Pakistan, Peru and Canada.

With many families and infertile couples needing an alternative to their infertility problems, The Dean thinks that $IVOB‘s pioneer product is part of a needs-based market that has a strong pre-existing demand!

Upon FDA approval, the INVOcell will be available as a fertility solution in hundreds of clinics and centers in the United States! In a country where the media and celebrities drive consumer wants and spending, The Dean thinks it won’t take much for the genius of INVOcell to spread throughout the United States and translate into further GAINS for $IVOB!

Still haven’t signed up to be an Honor Student? What are you waiting for?!

UPTR closed above $0.50 for the first day in a while on strong volume. The 90-day chart is a good upturn indicator of the short-term spike in trading volume that could move the stock much higher. I just noticed http://www.TheUpTurnStock.com has been updated again which in my experiences means there is more stock promotion on its way.

ADAT is up 100% this week on record volume and I don’t expect it to slow down as long as the volume keeps up. This penny stock play hasn’t traded this much dollar volume since it was trading $1.50-$3 back in 2006-2007.

SAAS is another internet stock with the “Software as a Service” or (“SaaS”) business model that may follow exactly what ADAT does… or visa versa considering they’ve both doubled in the past week.

JCDA is very illiquid but the company is scheduled to release earnings on May 21st and it should continue trading higher into that announcement.

INOD is another one I’ll keep my eye on since its approaching the Dec ’07 high of $6.00 and could run wild after that.

ARTG is another SaaS technology company that I see moving quickly above $4.

CHINA appears to have found a short-term bottom after touching $1.54 and I’m looking for it to break out back above $1.80.

LIOX will likely continue to move higher after a Motley Fool 5 Star Report.

OPWV finished up 17% on Tuesday after announcing an expansion plan into emerging markets.

ORCC provides outsourced web- and phone-based financial technology services. I’ll remain on the sidelines until it trades 3 days in a row above the 90-day average volume.

IPAS will continue higher with the rest of the peer group IMO looking for same 90-day volume indicator as above.

That is it for today’s issue of The Dean’s List on the webs #1 rated penny stock school.

WWAG is up 7 of the past 8 days and I expect it to break out above $1 any day now.

KAZ is a oil and gas stock that traded up 66% on Friday and I’m still long because the P/E is still well under 3… making this a potential earnings momentum runner on deck.

QELP is another oil and gas stock very similar to KAZ and I’m bullish here as well.

LEE is my #1 potential short because the stock tripled in price last week despite announcing horrific quarterly results. Friday was the first semi-sideways day and unless LEE acts very strong on Monday I’ll be shorting it.

LEA was mentioned in a Barron’s report as a “name that could be in trouble” and taking advantage of this negative publicity to short the stock.

AXL is another potential short I’m watching very closely. If it trades negative and/or moves sideways I may short into the weakness.

MEDQ released its 10-Q on Thursday 5/7/09 and it gapped up on Friday, closing up 57%. IMO this stock is still on deck as an earnings runner and will continue trending higher.

PLM doubled in price last week and when momentum cools off (negative on the day + one hour of sideways action) I will short this stock.

GOK announced record quarterly results after the closing bell on Thursday that sent the stock up 61% on Friday with massive volume. I expect the volume to continue today and this could be another big earnings runner.

SUMT appears to have hit a lot of resistance in the $4.50-$4.60 range after Wednesday’s announcement that Vista Equity Partners has offered to buy all shares outstanding for $4.50 per share. Despite this news it could have $0.50-$0.75 downside because (1) its up +300% in 90 days and (2) nothing but sideways price action the past few days.

WWAG finally had a down day after 6 straight days in the green. If this dips below $0.50 it could be a good buying opportunity as long as the volume continues.

HEB is one of the higher beta swine flu stocks and I’m rooting for this one to go higher so I can short the swine flu hype.

LEA is one of many insolvent stocks taking off for no apparent reason. Since it’s a U.S. based auto company I’m willing to bet that earnings won’t be earth-shattering but the company has already started hyping up the earnings announcement. I’m shorting once it shows signs of slowing down (volume and/or price fading).

SPPI will likely trade higher on Friday with insiders disclosing stock purchases Thursday after the closing bell a la 8K HERE.

HNSN finished up 28% today after announcing an agreement with GE about a partnership that enables the companies to promote the compatibility of the GE Innova X-ray imaging platform with Hansen medical’s sensei® Robotic Cather System.

GCA announced a quarterly net income of $0.12 per share and will likely sustain its momentum in the short-term so I’m buying on the big dips.

BONT has run from $1.25 to +$4 despite announcing a 5% decrease in same store sales. Good stock for short selling IMO.

MNKD is rebounding nicely after an afternoon panic selloff drove it from $6.60 to $6.  A record # of shares traded during the afternoon freefall leading me to believe the momentum will continue for now.

Even ODP gained +20% today as the retail sector rallies on so-called “positive economic data.” This will be a great shorting opportunity once the market returns to sobriety.

PNCL announced quarterly EPS of $1.05 and the market didn’t react much at all to the news (average volume) despite (1) a string of earnings runners in the market and (2) a rare P/E under 3 for this small cap airline stock.

EPEX has now tripled from .20 to .60 despite announcing a record net loss for the most recent quarter. I’m reserving shares to short daily and will short when the opportunity knocks.

WWAG closed up another 16% today and has now gained 344% since The Dean filmed Class Trip: Dubai. The stock is well above its 52-week high and has very little resistance until $1.

NVAX is among the top performing swine flu stocks and it finished up 20% today after nearly collapsing the past few days. I’ve already shorted it once and will consider the same trade again.

ATRC gained 125% on earnings news despite the fact that Q1 net loss widened to $0.56/share. I don’t buy into this earnings play and will look to short instead.

ABD is scheduled to release earnings tomorrow and its already up from $1 to $3.60 in a few weeks. If the Street reacts well to numbers… this could go to $7-$10 with ease.

BEE is trading with unprecedented volume and I expect the stock will continue trending higher if the volume continues.

MNKD closed up 31% today and is at a new 52-wk high. It’s risen from $2 to $5.45 during the past 10 weeks and will make a prime short selling opportunity soon.

XTXI is near the resistance previously set in early 2009. If it can breakout above $6 than it could quickly see $10 or more.

SAH is due to release earnings in Friday May 8th and I’d expect the momentum to continue until then.

Below is The Dean’s List for 5/5/09 featuring penny stock promotions, swine flu stocks, earnings runners and more!

WWAG finished up another 30% today and is now up 281% since I first initiated coverage on the stock. I’m looking for the momentum to carry this one above $1.

NVAX is down 33% since The Dean’s Trade and I’m still convinced the stock has another quarter or two to the downside.

BCRX is another swine flu stock that I’ve covered before and like the rest of the peer group I am shorting them all since the swine flu hype machine flaked out.

HGSI is the 3^rd swine flu stock on The Dean’s List today and like the others— I’m shorting it. HGSI actually has the most downside potential of the peer group.

KFN continues to rally and is now up +370% since early March. This stock will make a fantastic short but not until the time is right.

CPSL was a long on yesterday’s edition of The Dean’s List and it finished up 54% today. CPSL is a great earnings runner and will continue its strength as long as the broader market holds up.

CAEI is another long since its small cap mania for China stocks with good earnings.

LIZ has a lot of upside potential but it’s ultra risky considering its up from $2 to $6.30 during the past 6 weeks.

WWAG closed at $0.47 on Friday for a one-day gain of 27%. This is The Dean’s #1 pick for 2009 and I just saw that stock promoters including 24-7stockalert.net and dubaipennystocks.com just mentioned WWAG.

NVAX had a panic sell-off on Thursday afternoon (4/30) about an hour after I wrote THIS blog entry. In my opinion this stock has the most downside of all swine flu stocks on The Dean’s List of Swine Flu’s.

BCRX is another swine flu stock that I believe will drop more once the mania subsides.

COIN is a momentum stock that has a lot more upside as long as this Bear Market Rally is contained. If it ends abruptly COIN may eventually make a good short.

PQ is another momentum stock that has an earnings announcement on Tuesday May 5^th at 9am. Until then I’d expect the momentum to continue.

KFN is setting up for a great short sale but not quite yet. I am watching this stock very closely and reserve shares daily to short.

CPSL is another china small cap stock with momentum and I’m bullish.

CQB reported Q1 results on 4/30 and the Street is responding positively. This is one of many earnings runners that may continue trending higher.

CSV has a very impressive looking chart and should be on everybody’s watch list.

AGTI is a stock promotion by hototc.com, stockegg.com and thestockprophet.com and will likely gap up early morning as a result.

LNET is up about 28% since being one of The Dean’s Trades on 4/23 and it’s at an important technical level. It has lots of resistance dating back to August 2008 (notice the sideways price action) and if it can break out above this resistance it could quickly pop to $5-$6.

ONTY was the perfect shorting opportunity earlier today and luckily it rebounded nicely, setting up for another perfect shorting opportunity! Today’s sell-off has probably spooked a lot of investors so I expect tomorrow to be a prime day for short sellers.

EVII is being promoted by a few powerful penny stock promoters including 24-7stockalert.net, stockpreacher.com, hototc.com and stockegg.com. The Dean always follows stock promotions by these groups and may go long if it doesn’t gap up.

DDRX finally showed signs of weakness today and I’m anticipating a big sell-off soon. The stock is up 1,633% during the past month and despite the fact that they posted an impressive quarterly net income- 1,633% in a month isn’t sustainable. This is my #1 potential short.

MDOR is up 400% over the past month and all the signs indicate that it will make an excellent short once it shows some weakness. The insiders are dumping, they’ve received financing on terrible terms and illegal stock promotion is taking place by NYTimesReport.com (FYI see my blog about NYTimesReport HERE).

NVAX is the top performing swine flu play on The Dean’s List of swine flu stocks and is up 293% since 4/23. This could go higher but it’s not worth the risk. I will short NVAX once it: (a) gaps up a lot, (b) spikes intra-day due to short squeeze or (c) closes down for the day and fails to show strength the following morning.

MNTG closed up nicely and the only information I can find is a Form 13G filing confirms that Private Management Group, Inc. now owns 4.98% of the shares outstanding. They know something we don’t know and I expect MNTG to trend higher into their 5/7/09 earnings announcement.

Swine Flu is all the craze on Wall Street and I decided to tally up the score of The Dean’s List of swine flu stocks. Keep in mind that I’ve been updating this list regularly and it now contains 24 stocks moving on swine flu mania:

(NVAX) +111.27%
(ADLS) +7.06%
(BCRX) +75.11%
(GNVC) +7.81%
(DVAX) +29.67%
(HEB) +32.67%
(HGSI) +7.69%
(IMM) +3.67%
(INSM ) -0.84%
(SVA) +34.01%
(VICL) +11.84%
(MCET) +15%
(HALO) -2.58%
(AVII) +15.73%
(XOMA) +11.02%
(LWLLE) +180%
(CBMX) +1.85%
(CERS) +20.18%
(CRXL) +6.49%
(GNBT) +44.78%
(NNVC) +40.00%
(PPHM) +7.20%
(QDEL) +6.50%
(SIGA) -0.97%

My list of swine flu stocks has gained an average of 27.71% in about 4 hours. Granted most of them did gap up quite a bit… but it’s been quite a while since we’ve seen ‘Mania Movers’ up +100% or more. It’s almost like the dot com days of old.

Worth noting is the #1 gainer LWLLE was promoted by Lebed.biz. At exactly 9:39am he sent out an email newsletter hyping exaggerating pumping discussing the stock and by 9:44am it had gained 200%. This is a real testament as to how fast some of these stock promotion plays can run (see chart below).

Congratulations to everyone who took the time to research The Dean’s List of Swine Flu stocks and be on the lookout for more runners because I don’t think ‘Swine Mania’ is over quite yet.

The Dean’s List for Monday 4/27/09 only contains penny stocks that may outbreak breakout due to the Swine Flu epidemic. One of The Dean’s top students is an expert in the field of Pharmacy and together we’ve developed a list of 12 potential Swine Flu plays. Our segmentation strategy was to focus on respiratory-related biotech stocks with existing momentum. It’s a pure gamble which of these stocks will catch ‘Swine Mania’ but the upside potential can be astronomical.

NVAX uses a virus-like particle platform technology for infectious diseases including multiple strains of influenza, H5N1, shingles and Respiratory Syncytial Virus.

ADLS has a leading candidate called Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pnemonia. It’s also completed Phase III clinical trials for the treatment of respiratory tract infections.

BCRX engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

GNVC is developing a product called TherAtoh, a potential vaccination for respiratory syncytial virus, HSV-2, malaria, HIV and foot-and-mouth disease.

DVAX products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases.

HEB develops multiple products for the treatment of West Nile Virus, SARS, genital wards and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.

HGSI development pipeline includes drugs to treat inhalation anthrax, hepatitis C and lupus.

IMM programs include hepatitis C virus, fungal diseases, and multi-drug resistant strains of bacterial infections.

INHX develops anti-infective products to treat serious infections including shingles, chicken pox and herpes.

INSM engages in the development of recombinant protein drugs. Their IPLEX product is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions.

SVA engages in the sale of vaccines that protect against human infectious diseases primarily in China. Their Anflu drug provides a split virus influenza vaccine.

VICL develops products based on its DNA delivery technologies for the prevention and treatment of diseases including H5N1 pandemic influenza virus and cytomegalovirus.

MCET has a $1.4M market cap and is trading at $0.01. According to the company’s website, their MCT-465 drug candidate is a Toll-like Receptor (TLR) agonist, and is indicated as prospective therapy for treatment of virus infections including influenza A H1N1 and the “avian flu” virus.

HALO has a treatment called Gammagard. It’s a sterilized solution made from human plasma that contains the antibodies to help your body protect itself against infection from various diseases. A $30 billion company, Baxter International (BAX), has partnered with HALO for the distribution of Gammagard and must pay royalties for its use.

AVII is developing drugs for the treatment of rare viruses and conducts research in collaboration with the U.S. Army. The majority of this collaboration has been supported by a research contract from the Department of Defense’s Transformational Medical Technologies Iniative with the goal of developing new antiviral drugs.

XOMA is currently engaged in more than 16 active development projects across multiple therapeutic areas including autoimmune and infectious disease. The company has ongoing contracts with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) to develop monoclonal antibody products.

LWLLE is engaged in the development, manufacture, sale and distribution of disinfectant health care products including hand disinfectants, surface disinfectants, equipment disinfectants, machine disinfectants and animal disinfectants.

CBMX has also developed a semiconductor-based DNA chip, the CombiMatrix Influenza A Research Microarray, that can detect and accurately type flu strains with hemagglutinin subtypes 1 through 15 and neuraminidase subtypes 1 through 9 using a protocol that requires less than four hours start to finish. In addition to providing very high resolution information on genotype of any given flu strain, it can also provide information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu.

CERS has developed an INTERCEPT system that based on its proprietary Helinx technology for controlling biological replication.  The INTERCEPT system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

CRXL focuses on the development, production and marketing of vaccines and antibodies against infectious disease worldwide. Through its portfolio of core marketed vaccines, the company has established markets in hepatitis B, respiratory and travel vaccines.

GNBT technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.

NNVC is developing a nanoviricided branded as FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

PPHM is developing a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase II clinical trial for the treatment of solid tumors and HCV infection. The company has a third Phase I clinical study to evaluate the safety, pharmacokinetics and anti-viral activity of bavituximab over a longer dosing period in patients co-infected with HCV and the human immunodeficiency virus.

QDEL offers products for infectious diseases, such as Influenza, Group A Strep, and Respiratory Syncitial Virus; and for reproductive and women’s health, including pregnancy, Chlamydia, Bacterial Vaginosis, and Bone Health. It also offers Immunoassay fecal occult blood test used to detect the presence of blood in stool specimens; and Helicobacter pylori test, a serological test to measure antibodies circulating in the blood caused by the immune response to the H. pylori bacterium.

SIGA engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. It focuses on products for use in defense against biological warfare agents, such as smallpox and arenaviruses/hemorrhagic fevers.

GMED is a pink sheet company that uses hereditary information from DNA to improve patient outcomes. Targeted diseases include influenza, SARS, HIV, West Nile Virus and Hepatitis A, B and C.

NVLX sells nutraceutical products worldwide. The company’s Citroxin product is being tested on chicken embryos for bird flu in Thailand, as well as to eradicate the MRSA strain of staph in vitro. They also distribute  the ‘Immune Boost Bar’ designed to enhance overall immune function and help increase resistance to common viruses.

PURE develops silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides that are non-toxic solutions to numerous health challenges. PURE is also developing an EPA registered hard surface disinfectant known as Axen30. It disinfects twenty times faster than other disinfectants and provides a broad spectrum of protection as a disinfectant, fungicide and viricide.

I doubt any of these stocks will actually prevent or cure Swine Flu, but history proves that epidemic plays in the stock market can breakout to absurd prices.

References:
Yahoo covers Swine Flu Stocks

PFCB closed today up 20% on quarterly earnings growth of 39% YoY. PFCB could be the #1 short squeeze on this list after today’s announcement because the stock has 7.6M shares short as of 3/31/09. I’m long for the moment and wouldn’t be surprised if it reaches $40 before reversing.

GWGI finished up 16% on 10x average volume and the stock promotion is going full throttle with BestDamnPennyStocks.com, TopBestPennyStocks.com, 24-7stockalert.net and DubaiPennyStocks.com releasing email alerts. (it’s funny how StandOutStocks.com sends out GWGI email alerts and M2.com press releases to try and take credit).

NXTH is the latest stock promotion by hototc.com and stockegg.com and the compensation appears to be coming from a 3rd party (compensated by Winning Media on behalf of York Cassing Services Ltd) so that… plus the illiquidity… will keep me on the sidelines.

HOTT is on fire and if/when this Bear Market Rally subsides it’s one of the biggest opportunities among retail shorts. But until then I’ll maintain a spectator.

OPTR completely reversed its trend back in early Nov ’07 (on quarterly earnings alone?) but they’re still losing money so it doesn’t add up to me. From what I gather, OPTR is breaking out on a short squeeze (2.5M shares short as of 3/31 or about 8% of float). If so, OPTR may have $3-$5/share upside from here.

FRPT is one stock I’m sure most of you remember well. I see very little resistance between $8 and $10 so let the trend become your best friend.

BDSI is very near its previous highs (9/2/08 & April-May ’07) and I see more potential playing this as a short. As always I’m not looking to call a top and instead I’ll wait until a top is convincingly formed until I short.

CENT is a potential short squeeze (11% of Float) but the volume has been drying up the past few days. If it moving higher ($11-$12) than expect a massive short squeeze +$20. At first glance CENT looks like a great short but there are just too many existing shorts that would provide substantial downward support upon covering.

QTM——-Short. Today was the first down day after the stock tripled in a few weeks. This is my #1 short tomorrow (if it’s below $1.20) and will look for a major crack back towards $1 range.

TRE——-Long. TRE is up 2 days in a row and should continue trending upward after that nonsensical & one-sided report by Barron’s last week. I’m going long till $4. CAR——-Short. Exactly as I pointed out yesterday…. “CAR is a real company with real revenues but it’s spiked 443% in 30 days which is unsustainable. However, I won’t short until it cracks below $1.80.”

NTWK——-Short. Red hot stock promoter StockPreacher.com is a victim of his own success… because Tim Sykes & followers are shorting it and The Dean is likely go short as well if the stock shows morning weakness. If it can break support @ $0.60 than it could quickly drop down to $0.40-$0.50.

UIS——-Short. UIS finished down 26% today and if the broader market continues trending downward tomorrow (Tuesday) than I expect UIS to follow suit until its support around $1.

SPNG——-Long. Released a promising 10-Q late afternoon which boasts some impressive growth numbers. Besides the massive dilution et al RM Enterprises I think SPNG could have a big week. (BTW I’ve already covered my short @ $0.0165 for a small gain).